Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objective:
To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration.
Secondary Objective:
To assess:
Full description
Patients will be followed for 15 years after completion/early termination from the previous TDU13583 study (NCT01367444).
As the initial TDU13583 study is terminated - recruitment to this LTS13588 study is over with 27 patients enrolled.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must meet ALL of the following criteria:
Exclusion criteria
The following would exclude Patients from participation in the study:
Primary purpose
Allocation
Interventional model
Masking
27 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal